Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles

Journal of Nanobiotechnology

Research

Chin-Hsien Lin¹  Ming-Jang Chiu²  Herng-Er Horng³  Jen-Jie Chieh³  Bing-Hsien Liu⁴  Hsin-Hsien Chen⁴  Che-Chuan Yang⁴  Shieh-Yueh Yang⁵ 

[1] Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, 100, Taipei, Taiwan;Department of Neurology, National Taiwan University Hospital, College of Medicine, National Taiwan University, 100, Taipei, Taiwan;Graduate Institute of Brain and Mind Sciences, College of Medicine, National Taiwan University, 100, Taipei, Taiwan;Department of Psychology, National Taiwan University, 100, Taipei, Taiwan;Graduate Institute of Biomedical Engineering and Bioinformatics, National Taiwan University, 116, Taipei, Taiwan;Institute of Electro-optical Science and Technology, National Taiwan Normal University, 116, Taipei, Taiwan;MagQu Co., Ltd., Xindian District, 231, New Taipei City, Taiwan;MagQu Co., Ltd., Xindian District, 231, New Taipei City, Taiwan;Institute of Electro-optical Science and Technology, National Taiwan Normal University, 116, Taipei, Taiwan;

关键词: α-synuclein;    Parkinson disease;    Immunomagnetic reduction;   

DOI  :  10.1186/s12951-016-0198-5

 received in 2015-12-22, accepted in 2016-05-24,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundIt is difficult to discriminate healthy subjects and patients with Parkinson disease (PD) or Parkinson disease dementia (PDD) by assaying plasma α-synuclein because the concentrations of circulating α-synuclein in the blood are almost the same as the low-detection limit using current immunoassays, such as enzyme-linked immunosorbent assay. In this work, an ultra-sensitive immunoassay utilizing immunomagnetic reduction (IMR) is developed. The reagent for IMR consists of magnetic nanoparticles functionalized with antibodies against α-synuclein and dispersed in pH-7.2 phosphate-buffered saline. A high-Tc superconducting-quantum-interference-device (SQUID) alternative-current magnetosusceptometer is used to measure the IMR signal of the reagent due to the association between magnetic nanoparticles and α-synuclein molecules.ResultsAccording to the experimental α-synuclein concentration dependent IMR signal, the low-detection limit is 0.3 fg/ml and the dynamic range is 310 pg/ml. The preliminary results show the plasma α-synuclein for PD patients distributes from 6 to 30 fg/ml. For PDD patients, the concentration of plasma α-synuclein varies from 0.1 to 100 pg/ml. Whereas the concentration of plasma α-synuclein for healthy subjects is significantly lower than that of PD patients.ConclusionsThe ultra-sensitive IMR by utilizing antibody-functionalized magnetic nanoparticles and high-Tc SQUID magnetometer is promising as a method to assay plasma α-synuclein, which is a potential biomarker for discriminating patients with PD or PDD.

【 授权许可】

CC BY   
© The Author(s) 2016